Oncology Central

The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes


Targeted therapies based on molecular diagnostics have opened a new era of personalized medicine in lung cancer treatment. Recently, anaplastic lymphoma kinase (ALK) fusion gene emerged as an important biomarker for identifying a small proportion of non-small-cell lung cancer (NSCLC) patients that will benefit from ALK kinase inhibitor crizotinib, like EGFR activating mutations and EGFR tyrosine kinase inhibitors.

To view restricted content, please:

Leave A Comment